RHJA
TSHA icon

Rice Hall James & Associates’s Taysha Gene Therapies TSHA Stock Holding History

Rice Hall James & Associates’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.6M Buy
1,992,229
+47,558
+2% +$281K 0.66% 48
2026
Q1 		$8.69M Buy
1,944,671
+674,026
+53% +$3.13M 0.48% 56
2025
Q4 		$6.99M Buy
1,270,645
+692,527
+120% +$3.36M 0.38% 66
2025
Q3 		$1.89M Buy
+578,118
New +$1.64M 0.1% 164

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rice Hall James & Associates's TSHA Position: Q2 2026 in Review

Rice Hall James & Associates increased its Taysha Gene Therapies (TSHA) stake by 2.4% in Q2 2026, buying an estimated $281K and bringing the position to 1,992,229 shares worth $13.6M. The position accounts for 0.66% of the portfolio, ranked #48.

Rice Hall James & Associates first reported a position in TSHA in Q3 2025 and has held it in 4 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Rice Hall James & Associates held 1,992,229 shares of Taysha Gene Therapies worth $13.6M as of Q2 2026.
  • Rice Hall James & Associates bought 47,558 Taysha Gene Therapies shares in Q2 2026, an estimated $281K.
  • Taysha Gene Therapies made up 0.66% of Rice Hall James & Associates's portfolio in Q2 2026, its #48 holding.
  • Rice Hall James & Associates first reported a position in Taysha Gene Therapies in Q3 2025 and has held it in 4 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.